戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hroughs in the search for a highly effective tuberculosis vaccine.
2                 There is no highly effective tuberculosis vaccine.
3      There is an urgent need for an improved tuberculosis vaccine.
4 g strategy for an urgently required improved tuberculosis vaccine.
5 r many decades and in several countries as a tuberculosis vaccine.
6 nd may be of value in developing an improved tuberculosis vaccine.
7 ld facilitate the development of an improved tuberculosis vaccine.
8 or molecules, which may be novel targets for tuberculosis vaccines.
9 ate the rational down-selection of candidate tuberculosis vaccines.
10  T cell subsets will be important for future tuberculosis vaccines.
11 uberculosis, the "gold standard" for testing tuberculosis vaccines.
12 umber, and progression in the search for new tuberculosis vaccines.
13 s accordingly widely used as a model to test tuberculosis vaccines.
14  antigens and in measuring immunogenicity of tuberculosis vaccines.
15  the unique promise of CDNs as adjuvants for tuberculosis vaccines.
16  is the use case or rationale for developing tuberculosis vaccines?
17  the gaps in preclinical models for studying tuberculosis vaccines?
18                     What is the landscape of tuberculosis vaccines?
19 cal relevance of a novel virus-vectored (VV) tuberculosis vaccine administered via respiratory mucosa
20 e to the rational design of a new attenuated tuberculosis vaccine and the development of new diagnost
21 arch efforts are under way to develop cattle tuberculosis vaccines and specific diagnostic reagents t
22 berculosis infection with use of a candidate tuberculosis vaccine antigen, ID93, formulated in a synt
23 ective in newborns, only the hepatitis B and tuberculosis vaccines are given in the first 28 days of
24 culosis (TB) infection during childhood, new tuberculosis vaccines are necessary to disrupt the trans
25            Efforts to develop more effective tuberculosis vaccines are under way, but even if one is
26 his biomaterial by using the live attenuated tuberculosis vaccine bacille Calmette-Guerin (BCG).
27  rapidly after exposure, but how the current tuberculosis vaccine, bacillus Calmette-Guerin (BCG), im
28                               In Uganda, the tuberculosis vaccine BCG is administered on the first da
29                                            A tuberculosis vaccine candidate consisting of a 72-kDa po
30 a expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance respo
31 ells in the lungs of mice immunized with the tuberculosis vaccine candidate Mtb72F.
32 loped a live, fully attenuated Mycobacterium tuberculosis vaccine candidate strain with two independe
33  Here, we analyze immunity induced by a live tuberculosis vaccine candidate, recombinant BCG Deltaure
34 cines have been approved and three promising tuberculosis vaccine candidates are in late stage trials
35  vaccine 2 years ago, there have been no new tuberculosis vaccine candidates entering clinical testin
36                                Attenuated M. tuberculosis vaccine candidates have been constructed by
37 t effects, in addition to direct effects, of tuberculosis vaccine candidates in pivotal trials and la
38                                          New tuberculosis vaccine candidates that are in the developm
39 strategies for evaluation and development of tuberculosis vaccine candidates.
40           Older adults should be included in tuberculosis vaccine clinical development and implementa
41 be the development and characterization of a tuberculosis vaccine comprised of both antigen and adjuv
42 the generation of more creative diversity in tuberculosis vaccine concepts, the development of better
43 en parenterally, suggesting that respiratory tuberculosis vaccines could have an advantage in tubercu
44           Modelling studies suggest that new tuberculosis vaccines could have substantial health and
45                    Our results suggest novel tuberculosis vaccines could have substantial impact, whi
46               We simulated an M72-AS01E-like tuberculosis vaccine delivered from 2027 and estimated t
47 e reasons, highlighting a major challenge in tuberculosis vaccine design.
48 g questions, with the intention of informing tuberculosis vaccine development and the prioritisation
49                 But progress in the field of tuberculosis vaccine development has been hampered by th
50                                              Tuberculosis vaccine development is difficult and slow.
51                                              Tuberculosis vaccine development is hindered by the lack
52                                              Tuberculosis vaccine development strategies mostly targe
53 funded project STriTuVaD-In Silico Trial for Tuberculosis Vaccine Development-is supporting the ident
54  will facilitate the global pace of clinical tuberculosis vaccine development.
55  Our approach helps fill the gap in clinical tuberculosis vaccine development.
56 se findings also have implications for human tuberculosis vaccine development.
57  protection against disease would accelerate tuberculosis vaccine development.
58 Human challenge experiments could accelerate tuberculosis vaccine development.
59                      Assessment of candidate tuberculosis vaccine effectiveness with this optimized m
60                                     However, tuberculosis vaccine efficacy in mice is critically depe
61 n BCG-primed adults with an adenovirus-based tuberculosis vaccine elicits a repertoire of memory T ce
62  and could aid in the selection of candidate tuberculosis vaccines for field efficacy testing.
63            To address the gaps in developing tuberculosis vaccines for people with HIV, a series of s
64 s in a phase III trial of an investigational tuberculosis vaccine, greater baseline IFN-gamma respons
65 e no malaria vaccines and the only available tuberculosis vaccine had low efficacy.
66            The bacille Calmette-Guerin (BCG) tuberculosis vaccine has immunity benefits against respi
67          So far, research and development of tuberculosis vaccines has resulted in almost 20 candidat
68 ion of CD8 T cells to use with our candidate tuberculosis vaccine, ID93/glucopyranosyl lipid adjuvant
69 ical relevance of T cells induced by a novel tuberculosis vaccine in a phase 1 trial.
70 nally tested as an adjuvant within a subunit tuberculosis vaccine in neonatal mice.
71      We modelled the potential impact of new tuberculosis vaccines in China targeting adolescents (15
72             We estimated the impact of novel tuberculosis vaccines in low-income and middle-income co
73 cted MCMs, which may guide future testing of tuberculosis vaccines in nonhuman primates.
74 of follow-up and to evaluate the efficacy of tuberculosis vaccines in preventing clinical and subclin
75 has been made in research and development of tuberculosis vaccines in the past 20 years, and two clin
76 hly relevant to the development of candidate tuberculosis vaccines, including antigen 85b conjugated
77                          Whether a candidate tuberculosis vaccine induces clinically relevant protect
78 uating the efficacy of prevention of disease tuberculosis vaccines intended for preventing both clini
79 makers deciding whether and how to introduce tuberculosis vaccines into immunisation programmes.
80                                        A new tuberculosis vaccine is a high priority.
81          Bacillus Calmette-Guerin (BCG), the tuberculosis vaccine, is an attenuated mutant of Mycobac
82 Bacillus Calmette-Guerin (BCG), the existing tuberculosis vaccine, is known to induce heterologous ef
83                   Consequently, a successful tuberculosis vaccine may require the elicitation of sust
84  of BCG-primed CD4 T cells with heterologous tuberculosis vaccines may be best after 14 weeks of age,
85 te-Guerin (BCG), the only currently licenced tuberculosis vaccine, may exert beneficial non-specific
86  immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus Ankara exp
87 ogenicity of a live-attenuated Mycobacterium tuberculosis vaccine (MTBVAC).
88 rom a reported vaccine efficacy trial of the tuberculosis vaccine MVA85A in South Africa.
89            Groups B and D received candidate tuberculosis vaccine MVA85A.
90 in response to VACV and compared it with the tuberculosis vaccine Mycobacterium bovis bacille Calmett
91 e of death in AIDS patients, yet the current tuberculosis vaccine, Mycobacterium bovis bacillus Calme
92                           A new postexposure tuberculosis vaccine offers greatest potential for prote
93 ens that lead to defined epitopes for future tuberculosis vaccines or diagnostic tests, we aimed to c
94 ful licensure and deployment of an effective tuberculosis vaccine remain.
95                           Evaluations of new tuberculosis vaccines should account for the possibility
96                              The M72/AS01(E) tuberculosis vaccine showed 50% (95%CI: 2-74%) efficacy
97  found that Mycobacterium bovis BCG, a human tuberculosis vaccine, stimulated increased release of PG
98 discovered that Mycobacterium bovis BCG, the tuberculosis vaccine strain, is severely deficient in HI
99       Here, we tested the ability of oral M. tuberculosis vaccine strains expressing SIV Env and Gag
100 f new anti-tuberculosis drugs and attenuated tuberculosis vaccine strains.
101             Some of the most promising novel tuberculosis vaccine strategies currently under developm
102  to predict the protective efficacy of novel tuberculosis vaccines/strategies before they proceed to
103 elopment of BCG-vectored STING agonists as a tuberculosis vaccine strategy.
104  are necessary to guide development of novel tuberculosis vaccines that could facilitate the achievem
105                          Adolescent-targeted tuberculosis vaccines, the focus of many development pla
106 nical trial, making it the first recombinant tuberculosis vaccine to be tested in humans.
107 e pepA and PPE18 genes, is the first subunit tuberculosis vaccine to undergo phase I clinical trials.
108 t has been directed to develop Mycobacterium tuberculosis vaccines to boost bacille Calmette-Guerin o
109 translation of preclinically promising novel tuberculosis vaccines to ultimate human applications has
110                                 What are the tuberculosis vaccine trial design considerations?
111 cells/muL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania, we compared the
112 cells/muL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania.
113 sensus or debate on potential end points for tuberculosis vaccine trials among human immunodeficiency
114 ical tuberculosis as a composite endpoint in tuberculosis vaccine trials can help to reduce the sampl
115                                              Tuberculosis vaccine trials using disease as the primary
116 d to estimate the positive global effects of tuberculosis vaccine trials, in addition to informing po
117 res could enable radically shortened phase 3 tuberculosis vaccine trials.
118 uberculosis immunization policies and future tuberculosis vaccine trials.
119 could be evaluated as a proxy for disease in tuberculosis vaccine trials.
120    The two-dose regimen of the M72/AS01(E-4) tuberculosis vaccine was immunogenic, with an acceptable

 
Page Top